Annual reports filed by certain Canadian issuers pursuant to Section 15(d) and Rule 15d-4

Consolidated Statements of Financial Position

v3.19.3.a.u2
Consolidated Statements of Financial Position - USD ($)
Dec. 31, 2019
Dec. 31, 2018
Current assets    
Cash and cash equivalents $ 306,019,000 $ 117,967,000
Short term investments (note 5) 0 7,889,000
Accounts receivable and accrued interest receivable 368,000 217,000
Prepaid expenses and deposits 8,750,000 6,775,000
Current assets 315,137,000 132,848,000
Clinical trial contract deposits 209,000 358,000
Property and equipment (note 6) 93,000 41,000
Acquired intellectual property and other intangible assets (note 7) 11,244,000 12,616,000
Assets 326,683,000 145,863,000
Current liabilities    
Accounts payable and accrued liabilities (note 8) 11,177,000 7,071,000
Deferred revenue (note 10) 118,000 118,000
Contingent consideration (note 11) 0 72,000
Current liabilities 11,295,000 7,261,000
Deferred revenue (note 10) 206,000 324,000
Contingent consideration (note 11) 5,113,000 3,956,000
Royalty obligation (note 12) 7,200,000 0
Derivative warrant liabilities (note 13) 29,353,000 21,747,000
Liabilities 53,167,000 33,288,000
Shareholders’ Equity
Common shares (note 14) 790,472,000 504,650,000
Contributed surplus 23,655,000 24,690,000
Accumulated other comprehensive loss (805,000) (805,000)
Deficit (539,806,000) (415,960,000)
Equity 273,516,000 112,575,000
Equity and liabilities 326,683,000 145,863,000
Commitments and contingencies (note 20)